Eli Lilly and Company (LLY)
751.45 USD -25.27 (-3.25%) Volume: 6.04M
Discover the latest trends in Eli Lilly and Company’s stock price, currently valued at 751.45 USD. Despite a trading session decrease of 3.25% and a YTD drop of 2.66%, its high trading volume of 6.04M signifies robust market activity. Stay updated with LLY’s stock performance insights.
Latest developments on Eli Lilly and Company
Recent events have had a significant impact on Eli Lilly & Company’s stock price. A US judge sided with the FDA’s decision to remove Lilly’s weight loss drug from a shortage list, boosting investor confidence. Additionally, the company made headlines by licensing an early-stage ALS drug program from Alchemab in a $415 million deal. Despite a sell-off in the stock, analysts believe it was an overreaction and see potential for growth. With leadership transitions and strategic partnerships in place, Eli Lilly is poised to maintain its dominance in the obesity market and potentially steal Novo Nordisk’s weight-loss crown. The company’s commitment to bold science and groundbreaking facilities like the $4.5 billion medicine foundry in Lebanon further solidify its position in the industry.
A look at Eli Lilly and Company Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Eli Lilly & Company has a positive long-term outlook. With high scores in Growth and Momentum, the company is positioned for future success in the pharmaceutical industry. The company’s focus on innovation and development of new products is reflected in its strong Growth score, while its ability to maintain a strong market position is evident in its high Momentum score.
Eli Lilly & Company’s overall outlook is further supported by its respectable scores in Dividend and Resilience. While the Value score is lower compared to other factors, the company’s strong performance in other areas indicates its potential for continued growth and success in the market. With a diverse product portfolio that includes pharmaceuticals for both humans and animals, Eli Lilly is well-positioned to thrive in the global healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
